Feng Zhou - China SXT Chairman CEO
| SXTC Stock | USD 0.38 0.01 2.56% |
Insider
Feng Zhou is Chairman CEO of China SXT Pharmaceuticals
| Age | 32 |
| Address | 178 North Taidong Road, Taizhou, China, 225300 |
| Phone | 86 523 8629 8290 |
| Web | https://www.sxtchina.com |
China SXT Management Efficiency
The company has return on total asset (ROA) of (0.0497) % which means that it has lost $0.0497 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2165) %, meaning that it created substantial loss on money invested by shareholders. China SXT's management efficiency ratios could be used to measure how well China SXT manages its routine affairs as well as how well it operates its assets and liabilities. As of November 25, 2024, Return On Tangible Assets is expected to decline to -0.14. The current year's Return On Capital Employed is expected to grow to -0.17. At present, China SXT's Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Intangible Assets is expected to grow to about 34.3 K, whereas Total Assets are forecasted to decline to about 21.9 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Yoshihiro Furuya | Shionogi Co Ltd | N/A | |
| Eugene III | Biofrontera | 39 | |
| Sigal Aviel | Painreform | 60 | |
| YatGai Au | Regencell Bioscience Holdings | 51 | |
| Patricio Munoz | Procaps Group SA | 51 | |
| Tejinder Virk | Akanda Corp | 42 | |
| Erica CPA | Biofrontera | 39 | |
| MBA MBA | Painreform | 55 | |
| Keith Lavan | Petros Pharmaceuticals | 60 | |
| BCom BAcc | Akanda Corp | 44 | |
| Michael Starkweather | Shuttle Pharmaceuticals | 40 | |
| Hermann Lubbert | Biofrontera | 68 | |
| Michael Hoek | Shuttle Pharmaceuticals | 64 | |
| CSC MD | Shuttle Pharmaceuticals | 57 | |
| Pr Hazum | Painreform | N/A | |
| Jeff Holm | Biofrontera | N/A | |
| Anatoly MD | Shuttle Pharmaceuticals | 80 | |
| Wai Chung | Regencell Bioscience Holdings | 47 | |
| Mitchell MBA | Petros Pharmaceuticals | 60 | |
| BComm BCom | Akanda Corp | 68 | |
| Michelle Chan | Regencell Bioscience Holdings | N/A | |
Management Performance
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.0497 |
China SXT Pharmaceuticals Management Team
Elected by the shareholders, the China SXT's board of directors comprises two types of representatives: China SXT inside directors who are chosen from within the company, and outside directors, selected externally and held independent of China. The board's role is to monitor China SXT's management team and ensure that shareholders' interests are well served. China SXT's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, China SXT's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Feng Zhou, Chairman CEO | ||
| Xiaodong Pan, Chief Officer | ||
| Jun Zheng, Executive Director |
China Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is China SXT a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.0497 | ||||
| Profit Margin | (1.61) % | ||||
| Operating Margin | 7.34 % | ||||
| Current Valuation | (7.87 M) | ||||
| Shares Outstanding | 4.06 M | ||||
| Shares Owned By Insiders | 16.94 % | ||||
| Shares Owned By Institutions | 1.34 % | ||||
| Number Of Shares Shorted | 105.3 K | ||||
| Price To Earning | 5.73 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether China SXT Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of China SXT's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of China Sxt Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on China Sxt Pharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in China SXT Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Personal Care Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China SXT. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China SXT listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.426 | Earnings Share (3.57) | Revenue Per Share 2.223 | Quarterly Revenue Growth 0.295 | Return On Assets (0.05) |
The market value of China SXT Pharmaceuticals is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China SXT's value that differs from its market value or its book value, called intrinsic value, which is China SXT's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China SXT's market value can be influenced by many factors that don't directly affect China SXT's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between China SXT's value and its price as these two are different measures arrived at by different means. Investors typically determine if China SXT is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China SXT's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.